Neose Technologies, Inc. Announces GlycoPEG-GCSF Abstract Accepted for Poster Presentation at IXth World Conference on Clinical Pharmacology and Therapeutics
Published: Jul 28, 2008
HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company’s collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics. The International Union of Basic and Clinical Pharmacology is hosting this Annual Scientific Meeting in Quebec City, Canada from July 27-August 1, 2008. The abstract is entitled “GlycoPEGylated G-CSF XM22 Demonstrates Sixty Percent Higher Bioavailability and Thirty Percent Greater Neutrophil Response in Comparison to Pegfilgrastim in Healthy Volunteers after Single Body Weight Dependent and Fixed Dose” and will be presented on July 30, 2008.